Policy & Regulation
MicroGenDX announces launch of SARS-CoV-2 whole genome variant identification
7 April 2021 -

DNA sequencing company MicroGenDX on Tuesday unveiled the whole genome sequencing service COVID-19 Variant ID for identifying known variants of SARS-CoV-2 to combat the spread of emerging variants and gain understanding of the epidemiology of SARS-CoV-2.

With the emergence of new variants, the whole genome testing and research of SARS-CoV-2 may assist with discovering and describing new management approaches. The variants carrying the E484K mutation may escape immune response in some vaccinated individuals.

The company's COVID-19 Variant ID sampling product at less than USD300 includes instructions, collection supplies and prepaid shipping. It accepts specimen types for all COVID-19 testing, including nasopharyngeal swabs, nasal swabs, oropharyngeal swabs, sputum and saliva.

Prior to whole genome sequencing, the company will perform an rRT-PCR screen to determine if submitted samples are acceptable for sequencing. Final sequencing results will be available five to six business days after receipt of sample.



Related Headlines